|
|
|
|
| LEADER |
05256nam a2200709 4500 |
| 001 |
ocn864744144 |
| 003 |
OCoLC |
| 005 |
20170124072149.5 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
131206s2014 gw ob 001 0 eng d |
| 040 |
|
|
|a IDEBK
|b eng
|e pn
|c IDEBK
|d EBLCP
|d DG1
|d N$T
|d YDXCP
|d OCLCF
|d OCLCQ
|d DEBSZ
|d COO
|d DEBBG
|d OCLCQ
|d CDX
|d GrThAP
|
| 019 |
|
|
|a 870511683
|a 961643563
|a 962637366
|
| 020 |
|
|
|a 9783527677283
|q (electronic bk.)
|
| 020 |
|
|
|a 3527677283
|q (electronic bk.)
|
| 020 |
|
|
|a 9783527677252
|q (electronic bk.)
|
| 020 |
|
|
|a 3527677259
|q (electronic bk.)
|
| 020 |
|
|
|a 1306168902
|q (electronic bk.)
|
| 020 |
|
|
|a 9781306168908
|q (electronic bk.)
|
| 020 |
|
|
|a 9783527333943
|
| 020 |
|
|
|a 3527333940
|
| 020 |
|
|
|a 9783527677269
|q (Mobi)
|
| 020 |
|
|
|a 3527677267
|q (Mobi)
|
| 020 |
|
|
|a 9783527677276
|q (ePub)
|
| 020 |
|
|
|a 3527677275
|q (ePub)
|
| 029 |
1 |
|
|a DEBBG
|b BV043396386
|
| 029 |
1 |
|
|a DEBSZ
|b 43157054X
|
| 029 |
1 |
|
|a NZ1
|b 15495746
|
| 029 |
1 |
|
|a NZ1
|b 15905579
|
| 035 |
|
|
|a (OCoLC)864744144
|z (OCoLC)870511683
|z (OCoLC)961643563
|z (OCoLC)962637366
|
| 037 |
|
|
|a 548141
|b MIL
|
| 050 |
|
4 |
|a RS403
|
| 050 |
|
4 |
|a RM111
|b .L384 2013
|
| 060 |
|
4 |
|a QV 744
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.1/9
|2 23
|
| 049 |
|
|
|a MAIN
|
| 245 |
0 |
0 |
|a Medicinal chemistry approaches to personalized medicine /
|c edited by Karen Lackey and Bruce D. Roth.
|
| 264 |
|
1 |
|a Weinheim :
|b Wiley-VCH,
|c 2014.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Medicinal chemistry ;
|v Volume 59
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Methods and Principles in Medicinal Chemistry; Title Page; Copyright; List of Contributors; Foreword; Preface; A Personal Foreword; Acronyms; Chapter 1: Medicinal Chemistry Approaches to Creating Targeted Medicines; 1.1 Introduction; 1.2 Role of Medicinal Chemistry in Drug Discovery; 1.3 Evolution of Molecular Design for Subsets of Patients; 1.4 Combinations for Effective Therapies; 1.5 Biomarkers in Targeting Patients; 1.6 Emerging Field of Epigenetics; 1.7 Systems Chemical Biology; 1.8 Theranostics and Designing Drug Delivery Systems
|
| 505 |
8 |
|
|a 1.9 Rapid Progress in Further Personalizing Medicine ExpectedReferences; Chapter 2: Discovery of Predictive Biomarkers for Anticancer Drugs; 2.1 Introduction; 2.2 "Oncogene Addiction" as a Paradigm for Clinical Implementation of Predictive Biomarkers; 2.3 Cancer Cell Lines as a Model System for Discovery of Predictive Biomarkers; 2.4 Modeling Drug Resistance to Discover Predictive Biomarkers; 2.5 Discovery of Predictive Biomarkers in the Context of Treatment Combinations; 2.6 Discovery of Predictive Biomarkers for Antiangiogenic Agents; 2.7 Gene Expression Signatures as Predictive Biomarkers
|
| 505 |
8 |
|
|a 2.8 Current Challenges in Discovering Predictive Biomarkers2.9 Future Perspective; References; Chapter 3: Crizotinib; 3.1 Introduction; 3.2 Discovery of Crizotinib ( PF -02341066) [40]; 3.3 Kinase Selectivity of Crizotinib; 3.4 Pharmacology of Crizotinib [45,46]; 3.5 Human Clinical Efficacies of Crizotinib; 3.6 Summary; References; Chapter 4: Discovery and Development of Vemurafenib: First-in-Class Inhibitor of Mutant BRAF for the Treatment of Cancer; 4.1 Background; 4.2 Discovery and Development of Vemurafenib (PLX4032); 4.3 Pharmacology; 4.4 Clinical Efficacy and Safety
|
| 505 |
8 |
|
|a 4.5 Companion Diagnostic (cobas 4800) Development4.6 Synthesis; 4.7 Summary; References; Chapter 5: Targeting Basal-Cell Carcinoma: Discovery and Development of Vismodegib ( GDC -0449), a First-in-Class Inhibitor of the Hedgehog Pathway; 5.1 Introduction; 5.2 Hedgehog and Basal-Cell Carcinoma; 5.3 Cyclopamine as an SMO Antagonist; 5.4 Small-Molecule Inhibitors of SMO; 5.5 Preclinical Characterization of Vismodegib; 5.6 Vismodegib Clinical Experience in Phase I; References; Chapter 6: G-Quadruplexes as Therapeutic Targets in Cancer; 6.1 Introduction; 6.2 Quadruplex Fundamentals
|
| 505 |
8 |
|
|a 6.3 Genomic Quadruplexes6.4 Quadruplexes in Human Telomeres; 6.5 Quadruplexes as Anticancer Targets -- Evidence from In Vivo Studies; 6.6 Native Quadruplex Structures; 6.7 Quadruplex-Small-Molecule Structures; 6.8 Developing Superior Quadruplex-Binding Ligands; 6.9 Conclusions; References; Chapter 7: Identifying Actionable Targets in Cancer Patients; 7.1 Introduction and Background; 7.2 Overview of Genomic Sequencing and Its Impact on the Identification of Actionable Mutations; 7.3 Actionable Targets by Clinical Molecular Profiling: the OICR / PMH Experience
|
| 650 |
|
0 |
|a Pharmaceutical chemistry.
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Pharmaceutical chemistry.
|2 fast
|0 (OCoLC)fst01060115
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Lackey, Karen.
|
| 700 |
1 |
|
|a Roth, Bruce D.
|
| 776 |
0 |
8 |
|i Print version:
|t Medicinal chemistry approaches to personalized medicine.
|d Weinheim : Wiley-VCH, 2014
|z 9783527677252
|
| 830 |
|
0 |
|a Medicinal chemistry ;
|v Volume 59.
|
| 856 |
4 |
0 |
|u https://doi.org/10.1002/9783527677252
|z Full Text via HEAL-Link
|
| 994 |
|
|
|a 92
|b DG1
|
